Kathryn Durham

A once-nightly oral pill called AD109 has demonstrated statistically significant and clinically meaningful improvements in obstructive sleep apnea (OSA) in the largest pharmacotherapy clinical development program ever conducted for the condition.1,2 These results were from a pooled analysis of a pair of phase 3 trials, SynAIRgy and LunAIRo. They were presented at the 2026 American Thoracic Society (ATS) International Conference.

Survodutide led to significant weight loss among patients with obesity and overweight without type 2 diabetes (T2D), based on the phase 3 SYNCHRONIZE-1 trial.1 Announced by parent company Boehringer Ingelheim on April 28, 2026, these data reflect the efficacy of this investigational glucagon/GLP-1 receptor dual agonist.

On May 19, 2026, the US Food and Drug Administration (FDA) granted priority review to asundexian for secondary stroke prevention after non-cardioembolic ischemic stroke or transient ischemic attack (TIA).1 Announced by parent company Bayer, the filing is based on phase 3 OCEANIC-STROKE data presented earlier this year and published in The New England Journal of Medicine.